• MetVital Announces FDA Clearance AEO Testing for Glioblastoma Multiforme americanpharmaceuticalreview
    June 13, 2019
    MetVital announced the U.S. Food and Drug Administration (FDA) has notified MetVital that it may proceed with its clinical investigation of "Anhydrous Enol-Oxaloacetate" (AEO) as a potential treatment for patients with Glioblastoma Multiforme.
PharmaSources Customer Service